Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 9/20 | 0.64 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9514358 | 0.97 | HCAR2 (0.61) | HCAR2TSHRATMPOLBAPEX1 | |
| SCHEMBL195022 | 0.97 | HCAR2 (0.61) | HCAR2TSHRATMPOLBAPEX1 | |
| SCHEMBL1886812 | 0.93 | HCAR2 (0.58) | HCAR2TSHRATMPOLBAPEX1 | |
| SCHEMBL194313 | 0.93 | HCAR2 (0.58) | HCAR2TSHRATMPOLBAPEX1 | |
| SCHEMBL698817 | 0.93 | HCAR2 (0.58) | HCAR2TSHRATMPOLBAPEX1 | |
| SCHEMBL5082364 | 0.93 | HCAR2 (0.58) | HCAR2TSHRATMPOLBAPEX1 | |
| SCHEMBL2530701 | 0.93 | TSHR (0.63) | HCAR2TSHRATMPOLBAPEX1 | |
| SCHEMBL29132466 | 0.92 | HCAR2 (0.56) | HCAR2TSHRATMPOLBAPEX1 | |
| SCHEMBL28190015 | 0.91 | HCAR2 (0.56) | HCAR2TSHRATMPOLBAPEX1 | |
| SCHEMBL14007296 | 0.89 | HCAR2 (0.53) | HCAR2TSHRATMPOLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004673-B1 | Hair treatment composition comprising Michael addition product and methods for treating hair | L'OREAL (FR) | 2018-06-26 | — | — | US | claimed |
| EP-0325038-B1 | Surface priming composition for proteinaceous substrates, method of making and using same | OPI PROD INC (US) | 1993-11-03 | — | — | EP | claimed |
| US-4913939-A | Reaction product of cyclic anhydride and hydroxy compound; adhesion of adhesives | REM SYSTEMS, INC. (US) | 1990-04-03 | — | — | US | claimed |
| US-4863993-A | Surface priming composition for proteinaceous substrates; method of making and using same | OPI PRODUCTS, INC. (US) | 1989-09-05 | — | — | US | claimed |
| EP-0325038-A2 | Surface priming composition for proteinaceous substrates, method of making and using same | OPI PRODUCTS, INC. (US) | 1989-07-26 | — | — | EP | claimed |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-4114825-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-01-11 | — | — | EP | disclosed |
| US-20220121113-A1 | OXIME ESTER PHOTOINITIATORS HAVING A SPECIAL AROYL CHROMOPHORE | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| US-11209734-B2 | Oxime ester photoinitiators | BASF SE | 2021-12-28 | — | — | US | disclosed |
| US-11209733-B2 | Oxime ester photoinitiators | BASF SE | 2021-12-28 | — | — | US | disclosed |
| EP-3044208-B1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2021-12-22 | — | — | EP | disclosed |
| US-11204554-B2 | Oxime ester photoinitiators | BASF SE | 2021-12-21 | — | — | US | disclosed |
| WO-2006024617-A1 | COMPOSITIONS CONTAINING ANTHRAQUINONE DYES | HUNTSMAN ADVANCED MATERIALS (SWITZERLAND) GMBH (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006018405-A1 | OXIME ESTER PHOTOINITIATORS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-02-23 | — | — | WO | disclosed |
| EP-1567518-A2 | OXIME ESTER PHOTOINITIATORS WITH HETEROAROMATIC GROUPS | Ciba SC Holding AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050653-A2 | OXIME ESTER PHOTOINITIATORS WITH HETEROAROMATIC GROUPS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-06-17 | — | — | WO | disclosed |
| EP-0325038-B1 | Surface priming composition for proteinaceous substrates, method of making and using same | OPI PROD INC (US) | 1993-11-03 | — | — | EP | disclosed |
| US-4913939-A | Reaction product of cyclic anhydride and hydroxy compound; adhesion of adhesives | REM SYSTEMS, INC. (US) | 1990-04-03 | — | — | US | disclosed |
| US-4863993-A | Surface priming composition for proteinaceous substrates; method of making and using same | OPI PRODUCTS, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0325038-A2 | Surface priming composition for proteinaceous substrates, method of making and using same | OPI PRODUCTS, INC. (US) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11209734-B2 | Oxime ester photoinitiators | OR10J3, OXER1, QSOX1 | HCAR2 1784/4885TSHR 528/4885ATM 3078/4885 |
| US-11204554-B2 | Oxime ester photoinitiators | OR10J3, OXER1, QSOX1 | HCAR2 1610/4885TSHR 519/4885ATM 3037/4885 |
| US-11209733-B2 | Oxime ester photoinitiators | OR10J3, OXER1, QSOX1 | HCAR2 1784/4885TSHR 528/4885ATM 3078/4885 |
| US-10004673-B1 | Hair treatment composition comprising Michael addition product and methods for treating hair | SRM, CRAT, C9 | HCAR2 1735/4885TSHR 1844/4885ATM 1093/4885 |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | OCIAD1, OCIAD2, OXER1 | HCAR2 1233/4885TSHR 2202/4885ATM 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.